125 In schizophrenia, COX-2 inhibition showed beneficial effects preferentially in early stages of the disease, the data regarding chronic schizophrenia are controversial, possibly in part due to methodological concerns. The data are still preliminary and further research has to be performed, eg, with other COX-2 inhibitors. COX-2 inhibition as a possible anti-inflammatory therapeutic approach in depression Due
to the increase of proinflammatory cytokines and PGE2, in depressed patients, anti-inflammatory treatment would be expected to show antidepressant effects also in depressed patients. In particular, COX-2 click here inhibitors seem to show advantageous results: animal Inhibitors,research,lifescience,medical studies show that COX-2 inhibition can lower the increase of the proinflammatory cytokines IL-1β, TNF-α, and of PGE2, but it can also prevent clinical symptoms Inhibitors,research,lifescience,medical such as anxiety and cognitive decline, which are
associated with this increase of proinflammatory cytokines.122 Moreover, treatment with the COX-2 inhibitor celecoxib – but not with a COX-1 inhibitor – prevented the dysregulation of the IIPA-axis, in particular the increase of Cortisol, one of the biological key Inhibitors,research,lifescience,medical features associated with depression.122,126 This effect can be expected because PGE2 stimulates the HPA axis in the CNS,127 and PGE2 is inhibited by COX-2 inhibition. Moreover, the functional effects of IL-1 in the CNS – sickness behavior being one of these effects – were also shown to be antagonized by treatment with a selective COX-2 inhibitor.128 Additionally, COX-2 inhibitors influence the CNS serotonergic system. In a rat model, treatment with rofecoxib was followed by an increase of serotonin in the frontal and the temporoparietal cortex.129 A possible mechanism Inhibitors,research,lifescience,medical of the antidepressant action of COX-2 inhibitors is the inhibition of the release of IL-1 and IL-6. Moreover, COX-2 inhibitors also protect the CNS from effects of QUIN, ie, from neurotoxicity.130 In the depression model of the
bulbectomized Inhibitors,research,lifescience,medical rat, a decrease of cytokine levels in the hypothalamus and a change in behavior have been observed after chronic celecoxib isothipendyl treatment.131 In another animal model of depression, however, the mixed COX-1/COX-2 inhibitor acetylsalicylic acid showed an additional antidepressant effect by accelerating the antidepressant effect of fluoxetine.132 Moreover, we were able to demonstrate a significant therapeutic effect of the COX-2 inhibitor on depressive symptoms in a randomized, double-blind pilot add-on study using the selective COX-2 inhibitor celecoxib in MD.133 Also in a clinical study, the mixed COX-1/COX-2 inhibitor acetylsalicylic acid accelerated the antidepressant effect of fluoxetine and increased the response rate in depressed nonresponders to monotherapy with fluoxetine in a open-label pilot study.134 Currently, a large study with the COX-2 inhibitor cimicoxib is ongoing.